Margaret Patrick
United States
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Margaret Patrick
Two years in the making: seniors to debut their capstone performances
Senior Arianna Gaiser will debut her theatre production, “Lies,” this weekend. Collegian | Andrew Dixon For senior theatre majors Ariannah Gaiser and Sarah Nolting, procrastination could not be the answer to their senior capstone projects. These projects were two years in the making, and though they were cancelled last Spring due to COVID, the shows will be available to all audiences this weekend, Feb. 4 – 6. Nolting’s “Death and Renewal” will run Feb.
Tuning Internal Strain in Metal‐Organic Frameworks via Vapor Phase Infiltration for CO2 Reduction
Research Article Jing Gu Corresponding Author E-mail address: jingguchem@gmail.com San Diego State University, Department of Chemistry & Biochemistry, 5500 Campanile Drive , 92119 San Diego , UNITED STATES Search for more papers by this author PDF PDF Share Abstract Converting carbon dioxide (CO2) into sustainable fuels and chemical feedstock under mild conditions offers many opportunities for carbon‐neutral energy storage.
Stifel Gets Bullish on the Cannabis Sector in 2020
According to a report by Barron’s on January 7, Stifel analysts expect a rebound in the cannabis sector in the first half of 2020. This expectation follows an especially disastrous industry-wide performance in 2019. In the year, the Horizons Marijuana Life Sciences Index ETF (TSE:HMMJ) and the Cambria Cannabis ETF (BATS:TOKE) fell 37.41% and 37.88%, respectively.
Why Trump Has Banned Flavored e-Cigarettes
On January 2, as reported by CNBC, the FDA banned most fruit- and mint-flavored nicotine products. The move aims to reduce teen usage of these products. On December 31, CNBC reported that a senior White House official had disclosed the Trump administration’s plans to ban flavored e-cigarettes. The official, on condition of anonymity, told CNBC that only menthol- and tobacco-flavored e-cigarettes and flavored liquid nicotine products would be spared from the ban.
Canopy Growth Has Life, Say These Managers
On January 6, Canopy Growth (WEED) (CGC) rose 0.74% to 26.02 Canadian dollars on the TSE (Toronto Stock Exchange). It was also up 0.90% to $20.08 on the NYSE. The stock has taken a beating of 33.76% on the TSE since January 2, 2019. It fell 30.57% on the NYSE from January 2, 2019, to January 6, 2020. On January 6, CGC closed 62.07% lower than its 52-week high of 70.98 Canadian dollars and 42.74% higher than its 52-week low of 18.23 Canadian dollars.
CGC Has These Analysts Feeling Pessimistic
Cannabis stocks such as Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON), and Aphria (APHA) were some of the worst-hit stocks in 2019. The cannabis industry first suffered due to supply-side challenges in Canada. After this issue, the slower-than-anticipated retail rollout in Canada resulted in demand bottlenecks. Safety concerns—first associated with vaping and now with CBD—continue to haunt the sector.
Why MedMen Is Selling Its Assets
On December 31, Medmen’s (MMEN) (MMNFF) share price rose by 22.81% to 0.70 Canadian dollars on the CSE (Canadian Securities Exchange). The company’s shares also jumped by 21.39% to $0.53 on the US OTC (over-the-counter) exchange. Currently, MedMen’s shares are 81.77% lower than its 52-week high of 3.84 Canadian dollars on the CSE. The stock is also 94.44% above its 52-week low of 0.36 Canadian dollars.
Why Wall Street Revised HEXO's 2020 Estimates
On December 30, Hexo’s (HEXO) share price fell 4.38% to $1.53 on the NYSE. The stock also fell 4.76% to 2.0 Canadian dollars on the TSE. Most cannabis stocks, including Hexo, haven’t benefitted from the Santa Claus rally in 2019. Hexo stock is down 55.39% year-to-date on the NYSE and 61.61% on the TSE. The company’s shares fell 81.79% from its 52-week high of $8.40 on the NYSE, and the stock is just 3.38% above its 52-week low price of $1.48.
HEXO’s News to Raise $25 Million Spooks Investors
On December 26, HEXO (HEXO) announced a registered direct share offering for raising $25 million from institutional investors. The company is offering 14.97 million shares at $1.67 per share. HEXO plans to use the proceeds for working capital, R&D, and other general purposes. The company expects to close the offering by today. After this news, the company’s stock crashed by 21.74% and closed at $1.53 on December 26.
Cronos's 2020 Estimates See Revisions in December
On December 27, Cronos Group’s (CRON) share price fell 4.17% to 8.97 Canadian dollars on the TSE (Toronto Stock Exchange). The company’s shares, however, rose 0.88% to $6.88 on the Nasdaq. The stock is down YTD (year-to-date) by 41.75% on the TSE and 33.78% on the Nasdaq. Cronos stock has fallen 72.78% compared to its 52-week high of 32.95 Canadian dollars. The stock was also down 72.59% from its 52-week high of $25.10 on the Nasdaq.
Is Green Thumb a Good Buy in December 2019?
Green Thumb Industries (GTII) (GTBIF) is a cannabis CPG (consumer packaged goods) company and retailer with headquarters in Chicago, Illinois. The company is targeting an addressable market population of 151 million across 12 states in the US. Green Thumb’s major consumer cannabis brands include Rhythm, The Feel Collection, Dogwalkers, Beboe, and Incredibles. The company currently has 13 production facilities, 96 retail licenses, and 34 open stores across the US.
Is GW Pharmaceuticals a Good Buy in December 2019?
GW Pharmaceuticals (GWPH) is a leading player in the development of cannabinoid medicines. The company offers the first FDA-approved plant-derived cannabinoid medicine, Epidiolex oral solution. The regulatory agency approved it for two rare types of childhood-onset epilepsies. GW Pharmaceuticals stock is up YTD (year-to-date) by 3.04% on Nasdaq. On December 23, the stock closed 46.90% below the 52-week high of $196. Also, the stock is up by 1.93% from $102.11 on November 29 to $104.08 on December 23.
Major Institutional Investors Still in Cannabis Sector
On December 20, Curaleaf Holdings (CURA) (CURLF) announced a $275 million senior secured loan facility from a syndicate of lenders. Seaport Global Securities LLC is the placement agent for this transaction. According to CEO Joseph Lusardi, institutional investors are impressed with the company’s operational performance and credit profile. On December 2, Aphria (APHA) also announced a senior secured credit facility of $80 million for its subsidiary, Aphria Diamond.
Will Santa Claus Rally Boost Cannabis Stocks?
On December 26, as reported by CNBC, a Santa Claus rally seems to be in full swing. This calendar effect pushed the S&P 500 (SPX) and Nasdaq Composite Index (COMP) to record highs. S&P 500 Index rose YTD (year-to-date) by 29.24%. It closed at $3,239.91 on December 26. Nasdaq and Dow Jones hit record highs Also, Nasdaq breached the 9,000 level for the first time and closed at $9,022.39. Nasdaq is up YTD by 35.98%.
Is Acreage Holdings a Good Buy in December?
Acreage Holdings (ACRGF) is a vertically integrated cannabis MSO (multi-state operator) with a presence in 20 US states. The company also has cultivation and manufacturing operations across 1.2 million square feet in the US. Acreage Holdings has 88 dispensary licenses in the US market. Acreage Holdings stock has fallen 63.93% YTD (year-to-date) in the US OTC (over-the-counter) exchange. On December 20, the stock closed 77.13% below the 52-week high of $30.
Not All Analysts Believe ACB has Zero Value
On December 19, AltaCorp Capital analyst David Kideckel started coverage for Aurora Cannabis (ACB). He gave it a “Sector Perform” rating. He set ACB’s target price at $5.0. This implies an upside potential of 122.22% based on the last closing price. The analyst anticipates near-term challenges for the company mainly arising from the regulatory delays in Canada’s cannabis market. He remains concerned about the slower-than-anticipated retail rollout in Canada and the resultant supply-demand mismatch.
Why This Fund Manager Wants to Avoid Cannabis Stocks
On December 19, as reported by Cantech Letter, fund manager Norman Levine warned against investing in cannabis stocks in the current environment. The fund manager believes the cannabis sector to be a viable investment option. However, he is concerned about the current lack of profitability of the industry. He believes that even the industry leaders do not have good visibility about the timeline by which cannabis companies may turn profitable.
Linton Thinks Cannabis 2.0 Will Turn Things Around
On Wednesday, as reported by BNN Bloomberg, Bruce Linton expressed optimism about the cannabis sector after the Cannabis 2.0 launch. Canopy Growth’s (CGC) ex-CEO and Vireo Health’s current executive chairman explained that next-generation cannabis-infused products will attract more retail customers. As a result, he expects the retail demand for Cannabis 2.0 products to be a major factor behind increasing cannabis stocks in January and February.
HEXO's Q1 Earnings Were a Bit of a Letdown
HEXO (HEXO) released its first-quarter earnings results on December 16. Subsequently, the stock slid 13.84% from $2.24 on December 13 to $1.93 on December 18 on the NYSE. It also fell 13.89% from 2.95 Canadian dollars on December 13 to 2.54 Canadian dollars on December 18 on the TSE (Toronto Stock Exchange). Currently, the stock is down 43.73% YTD (year-to-date) on the NYSE and 51.25% on the TSE. HEXO closed 77.02% below its 52-week high of $8.40 on the NYSE.
Is Harvest Health a Good Buy This Month?
This year, Harvest Health & Recreation (HRVSF) (HARV) stock is down 58.01% on US OTC (over-the-counter) exchanges, and 59.10% on the CSE (Canadian Securities Exchange). Yesterday, the stock closed 79.72% below its 52-week high of $10.85 on US OTC exchanges. The stock has fallen by 14.06% from $2.56 on November 29 to $2.20 on December 17. Harvest Health also closed 73.27% below its 52-week high of 10.85 Canadian dollars on the CSE.
Is Curaleaf a Good Buy in December?
Curaleaf (CURA) (CURLF) stock is up year-to-date by 16.67% on the US OTC exchange. The stock is up 5.68% on the CSE (Canadian Securities Exchange). On December 16, the stock closed 54.39% below the 52-week high of $11.73 on the US OTC. The stock has taken a hit of 9.19% from $6.09 on November 29 to $5.53 on December 16. Curaleaf also closed 38.19% lower than its 52-week high of 11.73 Canadian dollars on the CSE.
Is Charlotte’s Web Holdings a Good Buy This Month?
Charlotte’s Web Holdings (CWEB) (CWBHF) stock is currently down 23.64% year-to-date on US OTC (over-the-counter) exchanges. Since May 31, the cannabis stock has fallen 37.36% on the TSE (Toronto Stock Exchange). On December 16, the stock was 66.41% below its 52-week high of $25.25 on US OTC exchanges. The stock fell by 12.85% from $9.73 on November 29 to $8.48 on December 16. CWEB also closed 62.79% lower than its 52-week high of 30.10 Canadian dollars on the TSE.
The Pros and Cons of Trading a Leveraged Cannabis ETN
On December 11, BNN Bloomberg reported the launch of the first-ever US leveraged ETN (exchange-traded note) for the cannabis sector. The MicroSectors Cannabis 2x Leveraged ETN is slated to start trading under the ticker symbol MJO on December 18 on the NYSE Arca. Connecticut-based REX Shares LLC designed this leveraged cannabis ETN. Scott Acheychek, the president of REX Shares, claimed the ETN would give investors exposure to the entire cannabis ecosystem.
An Overview of Canopy Growth and Its Brands
Canopy Growth (CGC) has been all over the news this month. On December 6, the company detailed its Cannabis 2.0 product rollout strategy. Plus, CGC announced the replacement of CEO Mark Zekulin with David Klein. Subsequently, the stock spiked by 14.15% and closed at $21.29 on the NYSE on December 9. However, the stock lost its upward momentum after analysts assumed a cautious stance for the company’s management change.
Canopy Growth: A Cannabis 2.0 Update
On December 6, Canopy Growth (CGC) disclosed its rollout plans for Cannabis 2.0 products, such as chocolates, vape pens, vape cartridges, and beverages. Cannabis 2.0 product formats became legal in Canada on October 17. However, licensed cannabis producers are required to give a 60-day notice to Health Canada prior to offering a new product for sale. Therefore, any new Cannabis 2.0 product can enter the market on December 16.
Was CGC a Big Mistake for Constellation Brands?
Canopy Growth (CGC) (WEED) has seen dizzying ups and gloomy downs in 2019. The stock jumped up by 79.91% from $28.92 on January 2 to $52.03 on April 29. Since then, the company has lost 35.59%. Today, CGC is down YTD (year-to-date) by 30.59% on NYSE. MORE bill still has a long way to go Previously, CGC had jumped up by 15.02% to $20.29 on November 21. The cannabis sector saw a short rally after House Judiciary Committee favored the MORE (Marijuana Opportunity Reinvestment and Expungement Act) bill.
Marijuana to Treat New Conditions in Minnesota
On December 3, as reported by MPRNews, Minnesota included chronic pain and age-related macular degeneration in the list of conditions eligible for treatment under the state’s medical marijuana program. This change would become effective in August 2020. The state’s Health Department also announced that it planned to expand the number of sites eligible for treating patients.
Is ACB Truly a Medical Company at Heart?
On December 2, Aurora Cannabis (ACB) announced approval for one of its cannabis oils under Ireland’s new MCAP (Medical Cannabis Access Programme). Physicians can now prescribe this cannabis oil for patients who experience multiple sclerosis-related spasticities, as well as severe and treatment-resistant epilepsy. These physicians can also prescribe ACB’s product for patients suffering from intractable nausea and vomiting due to chemotherapy.
Cannabis 2.0: Assessing CGC's Strategy
Cannabis 2.0 products have been legal in Canada since October 17, 2019. However, these cannabis-infused derivative products won’t appear in Canada’s physical or online stores until mid-December. This time gap between legalization and commercial entry stems from the requirement for licensed cannabis players to give a 60-day notice to Health Canada. This notice would inform the regulatory agency about the companies’ intent to sell new cannabis derivative products.
ACB: Can the US Cannabis Market Prove a Savior?
Aurora Cannabis (ACB) stock isn’t in the best shape today. As reported by BNN Bloomberg, the company’s CEO, Terry Booth, is justifiably worried about its shedding almost half of its market value YTD (year-to-date). As reported by MarketWatch, the recent downtrend in cannabis stocks is due to the disappointing results these companies have continued to post as recently as at the end of the latest earnings season.
Can CAUMZ End the Opioid Crisis in Mexico?
On December 2, Tetra Bio-Pharma (TBP) (TBPMF) announced an agreement with Alternavida S.A. de C.V. for the co-development and commercialization of CAUMZ in Mexico. According to the company’s investor presentation, CAUMZ is a cannabinoid-derived therapeutic comprising pure synthetic THC and CBD. The company is studying CAUMZ as an alternative for opioids for advanced cancer pain in an ongoing pivotal trial, SERENITY.
Cronos and Altria's Deal: Does It Make Sense Now?
Cronos Group (CRON), one of the more resilient cannabis stocks, hasn’t escaped the gloom in the cannabis sector. The stock is down 37.44% YTD (year-to-date) on the Nasdaq and 42.53% on the TSE (Toronto Stock Exchange). Previously, CRON had jumped 10.92% to $7.62 on November 21. Most cannabis stocks rallied after the Democratic-controlled House Judiciary Committee favored the decriminalization of marijuana at the federal level.
CGC Isn't Giving Analysts Much to Look Forward To
Canopy Growth (CGC) (WEED), the largest cannabis company by market cap, has definitely seen better days. Today, the stock is down 30.82% YTD (year-to-date) on the NYSE and 37.60% on the TSE (Toronto Stock Exchange). CGC is also down 64.75% from its 52-week high of $52.74 on the NYSE. Recently, the cannabis sector got some good news. On November 20, MarketWatch reported that the House Judiciary Committee had voted in favor of the MORE (Marijuana Opportunity Reinvestment and Expungement) bill.
Our Analysis of ACB’s Latest Financial Results
Once a hot favorite of analysts and investors, Aurora Cannabis (ACB) has become one of the worst-performing cannabis stocks of 2019. Year-to-date, the stock is down 49.60% on the NYSE and 53.17% on the TSE (Toronto Stock Exchange). On November 27, ACB stock rose 4.67% to 3.36 Canadian dollars on the TSE and 5.44% to $2.52 on the NYSE. Investors seem impressed with the company’s opening of an 11,000-square-foot flagship retail store in West Edmonton Mall, America’s largest.
Our Analysis of Aphria’s Fiscal 2020 First-Quarter Results
Aphria (APHA) emerged as one of the stronger cannabis companies in the latest earnings season. And since then, its stock has been more resilient than peers Aurora Cannabis (ACB), Canopy Growth (CGC), HEXO (HEXO), Cronos Group (CRON), and Tilray. Year-to-date, APHA is down 20.21% on the NYSE and 26.26% on the Toronto Stock Exchange. Meanwhile, ACB, CGC, HEXO, CRON, and TLRY are down 51.81%, 32.60%, 40.82%, 35.13%, and 71.58%, respectively, on US exchanges.
What's the Market Potential for CBD?
On November 25, the FDA issued warning letters to 15 companies involved in illegal sales of non-psychoactive CBD (cannabidiol) products, for not complying with the requirements of the Federal Food, Drug, and Cosmetic Act. The agency also expressed concerns about CBD’s safety in a consumer update. The FDA has listed liver injury, diarrhea, drug-drug interactions, drowsiness, and mood fluctuations as potential adverse events for CBD consumption.
MedMen Fights for Survival amid Sector Meltdown
On November 15, MedMen (MMEN) (MMNFF) declared an extensive five-year restructuring plan in its attempt to become EBITDA-positive by 2020. This plan mainly involves cutting costs, improving efficiencies, reducing cash outlays, and improving its overall company culture. However, investors seem to consider this move as a sign of desperation. After this news, the stock fell 3.43% on OTCMKTS to close at $0.98 on November 15.
Canopy Growth's Q2 Earnings: Good or Bad News?
Canopy Growth (WEED) (CGC) reported its second-quarter earnings results today. The stock is already down 16.07% on the day and is trading at 20.52 Canadian dollars on the TSE. Meanwhile, it’s down 16.11% to $15.52 on the NYSE. YTD (year-to-date), CGC is down 47.76% on the TSE and 46.33% on the NYSE. So why is the stock falling?
Illegal Vape Creates Opportunity for Legal Cannabis
Prohibition Partners expects the size of the legal cannabis market to be $103.9 billion by 2024. In “The Global Cannabis Report,” released this month, the firm forecast the size of the legal medical cannabis market to be $62.6 billion by 2024. Prohibition Partners also expects the legal recreational cannabis market to be worth $41.3 billion by 2024. Black market sales However, the legal cannabis market continues to face market share and revenue erosion from illegal players.
Aurora Cannabis Runs Mexico's Cannabis Market - Market Realist
Legal cannabis in Mexico is going through several twists and turns. The country first allowed medical marijuana in June 2017. On October 31, 2018, the Supreme Court of Mexico called the absolute ban on recreational cannabis as unconstitutional. This was the fifth time that the Supreme Court ruled in favor of recreational cannabis. According to the Court’s ruling, Congress had to make regulations for Mexico’s recreational cannabis legalization by October 2019.
Here's What GMP Says about Curaleaf
Curaleaf Holdings (CURA) (CURLF) had a great week. On October 30, as reported by CANTECH LETTER, GMP Securities analyst Robert Fagan restated the “Buy” rating. Also, he gave a target price of $24 Canadian dollars for the company. This implies an upside potential of 287.72% based on the company’s closing price of $6.19 Canadian dollars on November 1. Curaleaf’s last closing price is 87.08% lower than the 52-week high price of $11.73 Canadian dollars.
Could Angela Merkel Legalize Cannabis in Germany?
On October 26, DW reported that Angela Merkel’s party may be contemplating a move to legalize cannabis in Germany. On October 25, the CDU’s (Christian Democratic Union) interior policy spokesperson, Marian Wendt, highlighted the possibility of legalizing adult-use cannabis in Germany. However, he also expressed the need to control the production and distribution of marijuana.
Aurora Cannabis's Price Target Cut by 30%
Aurora Cannabis (ACB) stock is currently down 29.23% on the NYSE on a YTD (year-to-date) basis. The cannabis company has lost 14.81% of its value since October 1. Its stock is 71.98% below the 52-week high of $12.52 it reached on October 16, 2018. On the TSE (Toronto Stock Exchange), Aurora Cannabis is down 31.45% to 4.86 Canadian dollars YTD. Since October 1, the stock is down 10.66%.
What Legalizing Cannabis Means for Mexico
Mexico is fast approaching its October 23 marijuana legalization deadline. On October 10, Senator Julio Ramón Menchaca Salazar reiterated the deadline in the special joint meeting of the Mexican Senate’s parliamentary commissions of justice, health, and legislative study, according to Marijuana Business Daily. The senator has also promised to present the bill’s final draft by October 17.
Vaping and Cannabis Stocks: Piper Jaffray Weighs In
The vaping crisis is quickly proving to be an issue for the entire cannabis sector. On August 17, the CDC (Centers for Disease Control and Prevention) announced an ongoing investigation studying the link between pulmonary illnesses and e-cigarette use, or vaping. The investigation covered 94 cases of lung illnesses from 14 states in the US, which were all reported between June 28, 2019, and August 15, 2019. The number of potential cases investigated had swelled to 193 as of August 22.
Trouble at OrganiGram: Cooling Tower Concerns
Yesterday, CBC News reported the contents of an email circulated among OrganiGram (OGI) employees on August 13. According to the email, the company shut down several of its cooling towers and cleaned them due to high bacteria counts. The timing of this email coincides with a Legionnaires’ disease outbreak in western Moncton, New Brunswick, Canada. Health officials identified cooling towers as the source of the outbreak, though they did not reveal the exact source.
Canopy Growth: Getting Ready for Cannabis 2.0
Canada is gearing up for Cannabis 2.0, a second legalization phase scheduled for October 17. Subsequently, according to Deloitte, cannabis-infused edibles and other alternative products will become legal in the country. The new law opens a market worth 2.7 billion Canadian dollars annually. Of this total, Deloitte estimates the edibles market is worth 1.6 billion Canadian dollars.
Will Johnson & Johnson Become the Next Teva?
On Monday, an Oklahoma judge fined Johnson & Johnson (JNJ) $572 million for its part in fueling the opioid crises in the state. Johnson & Johnson fined in Oklahoma lawsuit The ruling is the first of its kind in the US. The court held the company responsible for downplaying the risks associated with opioid addiction. The landmark ruling will likely pave the way for the thousands of pending opioid-related lawsuits in Oklahoma.
Amazon Is Targeting a $9 Trillion B2B Opportunity
Amazon has been consistently impressing investors with its ability to identify and then disrupt underserved markets. The company has been focusing on a B2B (business-to-business) e-commerce opportunity through the Amazon Business marketplace, which it launched in 2015. Amazon Business customers can set up multiuser accounts to purchase products and services in this marketplace.
Is Amazon Moving into the Cryptocurrency Space?
Investors around the world expect Amazon (AMZN) to join the group of technology giants launching their own cryptocurrencies. These expectations have persisted despite Amazon Pay vice president Patrick Gaulthier making it clear that Amazon doesn’t wish to enter speculative areas. The rumors started in November 2017, when Domain Name Wire reported the company had registered three blockchain- and cryptocurrency-related domain names.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Margaret
Contact Margaret, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack